tp-0903
CLL
Sumitomo Pharma America, Inc.Phase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the CLL cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ppsv23 Region Örebro County | Phase 4 | BB |
Conjugated Pneumococcal Vaccine Region Örebro County | Phase 4 | BB |
Benadryl National Cancer Institute (NCI) | Phase 2 | B |
sb-497115-gr University of Ulm | Phase 2 | B |
Solu-Cortef Stanford University | Phase 2 | B |
View all 22 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →